Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes
Authors:
- 1 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (3) , 398-404
Abstract
Background: Pregnancy-associated plasma protein-A (PAPP-A) concentrations are increased in the circulation of patients with acute coronary syndromes (ACS) and are associated with future adverse cardiac events. PAPP-A in ACS differs from PAPP-A in pregnancy in that PAPP-A in ACS is not complexed with the proform of eosinophil major basic protein (proMBP). We investigated the effect of antibody selection on the utility of PAPP-A assays for measurement of PAPP-A in pregnancy and/or ACS, and whether immunoassays for PAPP-A in pregnancy are suitable for PAPP-A in ACS. Methods: We constructed 2-site sandwich time-resolved immunofluorometric assays using 22 monoclonal antibodies raised against pregnancy serum PAPP-A. All antibodies were studied in pairs, with each antibody used as either capture or tracer. We compared the reactivity of each antibody combination with PAPP-A/proMBP complex derived from pregnancy sera or with uncomplexed PAPP-A extracted from atherosclerotic plaques. Recombinant human PAPP-A and proMBP were also used to determine the specificity of the antibodies. We confirmed all major findings with serum samples collected from patients with myocardial infarction. Results: Six monoclonal antibodies reacted with the proMBP subunit of the PAPP-A/proMBP complex. Epitopes of 3 proMBP-reactive antibodies largely overlapped, but were well separated from those of another group of 3 proMBP-reactive antibodies. Assays using any of the 6 proMBP-reactive antibodies failed to detect PAPP-A in ACS. In addition, some 2-site assays capable of detecting PAPP-A in pregnancy were almost incapable of detecting PAPP-A in ACS, although the individual epitopes remained detectable in PAPP-A in ACS. Conclusions: Immunoassays developed for PAPP-A in pregnancy may not be suitable for PAPP-A in ACS. Assays for PAPP-A in ACS should be based on careful antibody selection and subjected to extensive testing with clinical ACS samples.Keywords
This publication has 28 references indexed in Scilit:
- Design and Validation of a Neutral Protein Scaffold for the Presentation of Peptide AptamersJournal of Molecular Biology, 2005
- Proteinase Inhibition by Proform of Eosinophil Major Basic Protein (pro-MBP) Is a Multistep Process of Intra- and Intermolecular Disulfide RearrangementsJournal of Biological Chemistry, 2005
- Molecular Distinction of Circulating Pregnancy-Associated Plasma Protein A in Myocardial Infarction and PregnancyClinical Chemistry, 2005
- Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patientsClinica Chimica Acta, 2004
- Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomesAmerican Journal of Obstetrics and Gynecology, 2004
- Inhibition of proteolysis by the proform of eosinophil major basic protein (proMBP) requires covalent binding to its target proteinaseFEBS Letters, 2004
- Complex of Pregnancy-associated Plasma Protein-A and the Proform of Eosinophil Major Basic ProteinJournal of Biological Chemistry, 2003
- Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary SyndromesNew England Journal of Medicine, 2001
- First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome.BMJ, 1992
- REFERENCE PREPARATION FOR ASSAY OF SOME PREGNANCY AND CANCER ASSOCIATED PROTEINSThe Lancet, 1980